The Latest SPAC News and Rumors: October 4, 2021


The Latest SPAC News and Rumors: October 4, 2021

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: MercadoLibre narrows its potential targets down to 30 firms, Mirion Technologies acquires Dosimetry Badge, and Redbox partners with Comcast’s FreeWheel

MercadoLibre SPAC Has 30 Latin America Tech Firms In Its Sights

E-commerce giant MercadoLibre Inc.’s blank-check company with venture capital firm Kaszek is just getting off the ground. Already, the e-commerce giant’s executives are mulling more partnerships in the region.

MELI Kaszek Pioneer Corp. raised $287 million in an offering that closed Friday. The SPAC has narrowed its potential targets down to a shortlist of 30 after considering 200 firms.


Mirion Technologies, Inc. Acquires US-based Dosimetry Services Distributor 

Mirion Technologies, Inc., a global provider of detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the acquisition of the Dosimetry Badge brand—a small, US-based distributor of personal dosimeter badges.

Mirion expects to complete its business combination with GS Acquisition Holdings Corp II (NYSE: GSAH) and become a publicly listed company in the second half of 2021.


Redbox Partners With Comcast’s FreeWheel to Bring Advertising Technology to Its Free Streaming Platform

Leading entertainment company Redbox today announced it will partner with FreeWheel, a Comcast Company that provides global technology solutions for the future of television advertising, to integrate programmatic technology across Redbox’s free streaming platforms. Through this technology, advertisers will be able to easily access and buy Redbox inventory and target specific audiences.

On May 17, Redbox entered into a definitive agreement to combine with Seaport Global Acquisition Corp. (NASDAQ:SGAM).


SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced that the first patient has been dosed with SAB-185 in the Phase 3 ACTIV-2 COVID-19 trial.

On June 22, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP). The transaction is expected to close in the fourth quarter of 2021.